Yanyu Bi

Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma

Cheng Chen, Kesang Li, Hua Jiang et al. · Cancer Immunology Immunotherapy · 2016 · 110 citations · Full text

Medicine, Immunology, Oncology +17

Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager

Yanyu Bi, Hua Jiang, Peng Wang et al. · Oncotarget · 2017 · 43 citations · Full text

Medicine, Immunology, Oncology +17

Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma

Kesang Li, Xiaorong Pan, Yanyu Bi et al. · Oncotarget · 2015 · 33 citations · Full text

Medicine, Immunology, Oncology +12

Rapamycin inhibits lung squamous cell carcinoma growth by downregulating glypican-3/Wnt/β-catenin signaling and autophagy

Yanyu Bi, Yiming Jiang, Xia Li et al. · Journal of Cancer Research and Clinical Oncology · 2020 · 23 citations · Full text

Life Sciences, Oncology, Pharmacology +16

Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN− glioblastoma <i>in vivo</i>

Wen Xu, Yanyu Bi, Juan Kong et al. · Oncotarget · 2016 · 16 citations · Full text

Medicine, Oncology, Pharmacology +17